Spontaneous Smoking Cessation Before Lung Cancer Diagnosis  by Campling, Barbara G. et al.
ORIGINAL ARTICLE
Spontaneous Smoking Cessation Before Lung Cancer
Diagnosis
Barbara G. Campling, MD,*† Bradley N. Collins, PhD,‡ Kenneth M. Algazy, MD,*†
Robert A. Schnoll, PhD,§ and Miu Lam, PhD
Introduction: We have observed that many patients with lung
cancer stop smoking before diagnosis, usually before clinical symp-
toms, and often without difficulty. This led us to speculate that
spontaneous smoking cessation may be a presenting symptom of
lung cancer.
Methods: Patients from the Philadelphia Veterans Affairs Medical
Center with lung cancer and for comparison, prostate cancer and
myocardial infarction underwent a structured interview about their
smoking habits preceding diagnosis. Severity of nicotine addiction
was graded using the Fagerstro¨m Test for Nicotine Dependence.
Among former smokers, dates of cessation, onset of symptoms, and
diagnosis were recorded. Difficulty quitting was rated on a scale of
0 to 10. Distributions of intervals from cessation to diagnosis were
compared between groups.
Results: All 115 patients with lung cancer had been smokers.
Fifty-five (48%) quit before diagnosis, and only six of these (11%)
were symptomatic at quitting. Patients with lung cancer who quit
were as dependent on nicotine, when smoking the most, as those
who continued to smoke, unlike the other groups. Despite this, 31%
quit with no difficulty. The median interval from cessation to
diagnosis was 2.7 years for lung cancer, 24.3 years for prostate
cancer, and 10.0 years for patients with myocardial infarction.
Conclusions: These results challenge the notion that patients with
lung cancer usually quit smoking because of disease symptoms. The
hypothesis that spontaneous smoking cessation may be a presenting
symptom of lung cancer warrants further investigation.
Key Words: Lung neoplasms, Prostate cancer, Myocardial infarc-
tion, Smoking cessation, Veterans.
(J Thorac Oncol. 2011;6: 517–524)
Lung cancer accounts for 27.6% of cancer deaths in the UnitedStates,1 and most cases are caused by smoking. Although not
widely recognized, it is well documented in cohort2–5 and
case-control studies6–8 that the risk of lung cancer among former
smokers exceeds that of continuing smokers for several years
after smoking cessation. It has been assumed that these smokers
quit because of symptoms of their cancer (the “quitting ill”
effect).4 However, we have observed that many patients with
lung cancer stop smoking spontaneously before diagnosis,
sometimes without making a conscious decision to do so, and
usually before the onset of symptoms. In a series of 178 patients
with lung cancer seen by Dr. Campling at the Kingston Regional
Cancer Centre (KRCC) in Canada from 1992 to 1994 (122 small
cell lung cancer [SCLC] and 56 non-small cell lung cancer
[NSCLC]), 174 had been smokers. Fifty-nine percent had
stopped smoking before diagnosis, and 65% of these were
asymptomatic from their cancer at the time of cessation9 (and
unpublished results). These observations led us to speculate that,
in some cases, spontaneous smoking cessation may be a pre-
senting symptom of lung cancer, possibly caused by tumor secre-
tion of a substance interfering with nicotine addiction. The purpose
of this study was to confirm and extend our clinical observations.
This is primarily a descriptive study of the incidence and
circumstances of smoking cessation before the diagnosis of lung
cancer. Patients with lung cancer from the Philadelphia Veterans
Affairs Medical (PVAMC) underwent a structured interview
with particular attention to the timing of smoking cessation in
relationship to onset of symptoms. In addition, for comparison,
we interviewed patients with prostate cancer and myocardial
infarction (MI). We expected that for prostate cancer and MI,
smoking cessation would reflect what is seen in the general
population, but this would not be the case for lung cancer. We
compared lifetime tobacco exposure and severity of nicotine
addiction among current and former smokers in the three groups.
Among former smokers, we compared the distribution of inter-
vals from cessation to diagnosis between groups. To determine
whether our results for veterans with lung cancer also apply to
other patients with lung cancer, we compared intervals from
cessation to diagnosis in the series of patients with lung cancer
seen at the KRCCwith those in the Veterans Affairs (VA) study.
METHODS
Patients
Veterans from the PVAMC were recruited from June
2004 until August 2006. Eligibility criteria included a diag-
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nosis of lung cancer, prostate cancer, or MI and availability
for an interview. Patients were identified from outpatient
clinic lists and a weekly lung tumor board. They were not
selected according to their smoking status. Surveys were
administered by trained interviewers who were blind to the
hypothesis. The study was approved by the Institutional
Review Boards of the PVAMC and the University of Penn-
sylvania, and all patients signed informed consent.
Procedures and Measurements
Participants were asked whether they had any symp-
toms before diagnosis, and if so, what these symptoms were,
and when they began. A cigarette smoker was defined as
anyone who had smoked at least 100 cigarettes in their
lifetime. All smokers were asked whether they currently
smoked, and if not, when they quit. Subjects who had ever
smoked were asked how old they were when they started,
how much they currently smoked, the most they had ever
smoked, and the number of years they smoked at least a pack
a day. The severity of nicotine addiction when smoking the
most was assessed using the Fagerstro¨m Test for Nicotine
Dependence (FTND).10 Subjects were also asked about con-
sumption of other tobacco products, and those who had
smoked only cigars or pipes on a daily basis were classified
as ever smokers.
Among subjects who had stopped smoking before di-
agnosis, their difficulty quitting and severity of withdrawal
symptoms were each recorded on a scale of 0 to 10, with 10
being most severe. Patients who continued to smoke were
asked whether they had cut down within 1 year of diagnosis,
and if so, by how much. Subjects were also asked whether
their weight had changed in the year before diagnosis, and if
so, by how much.
The type of cancer (lung or prostate) and date of
diagnosis of cancer or MI were obtained from medical
records. For lung cancer, the histological subtype was re-
corded as SCLC or NSCLC. The NSCLC cases were cate-
gorized as adenocarcinoma, squamous cell, large cell ana-
plastic, or other. Cancer stage was classified according to the
American Joint Committee on Cancer Staging System.11
Clinical records of those patients who had quit smoking
before diagnosis were reviewed to confirm their self-report of
whether they were symptomatic at the time of smoking
cessation.
Biochemical Validation of Smoking Status
After completing the interview, subjects were asked to
provide a saliva sample. Specimens obtained from patients
with lung cancer who claimed to be former smokers were sent
for cotinine analysis by gas chromatography-mass spectrom-
etry.12 Samples were analyzed by the Clinical Pharmacology
Laboratory, San Francisco General Hospital. Abstinence was
confirmed by a level of less than 15 ng/ml.13
KRCC Patients
In the series of 178 patients with lung cancer seen at the
KRCC from 1992 to 1994, four had never smoked, 71 were
current, and 103 were former smokers at diagnosis. These
patients were asked whether they had ever smoked, and if
they had quit, the approximate interval between cessation and
diagnosis. Intervals from cessation to diagnosis were re-
corded for all former smokers.
Statistics
Data were entered in an access database and analyzed
using SAS software (SAS Institute, Inc., Cary, NC). Descriptive
statistics were used to summarize the data. For comparisons
between groups, the 2 test was used for categorical variables,
and the Kruskal-Wallis test was used for continuous variables. A
p value of less than 0.05 was considered significant.
The Kaplan-Meier method was used to examine the
distribution of intervals from cessation to diagnosis.14 The
initial event was a diagnosis of lung cancer, prostate cancer,
or MI, and the time to event was the cessation to diagnosis
interval, which was derived retrospectively by former smok-
ers recalling when they quit. We also used the Kaplan-Meier
method to compare intervals from cessation to diagnosis
among former smokers from the VA and the KRCC, and
between former smokers with SCLC and NSCLC. In the
same manner, we examined the intervals from symptoms to
diagnosis among the VA patients with lung cancer. The
log-rank test was used for comparisons between groups.
RESULTS
Paticipants
During the recruitment period, 122 patients with lung
cancer were approached about the study, and 115 agreed to
participate. We also recruited 101 patients with prostate
cancer and 99 patients with MI. Only subjects who were
aware that they had an MI were approached. Table 1 sum-
marizes the patient characteristics. There were no major
differences in socioeconomic variables such as education,
income, employment, or marital status between the three
diagnostic groups or between current and former smokers
within the groups (data not shown).
Comparison of Current and Former Smokers
Across all groups, former smokers were older than
current smokers. This was most striking for lung cancer with
a median difference of 10 years. For both lung cancer and
prostate cancer, there was no significant difference in tumor
stage distribution between current and former smokers. For
lung cancer, there was no significant difference in histologic
subtype distribution of current and former smokers (Table 2).
For prostate cancer and MI, the lifetime tobacco expo-
sure was much less for former than current smokers, as
expected. In contrast, for lung cancer, there was no difference
in lifetime tobacco exposure between current and former
smokers. For severity of nicotine addiction, subjects were
asked to base their answers on the time in their lives when
they were smoking most heavily. For both prostate cancer
and MI, former smokers had lower FTND scores than current
smokers. In contrast, for lung cancer, the median FTND score
was high (7.0) for both current and former smokers.
Among current smokers with lung cancer, 38% reduced
their tobacco consumption by 50% within the year before
Campling et al. Journal of Thoracic Oncology • Volume 6, Number 3, March 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer518
diagnosis. Only 17% of current smokers with prostate cancer
and 4% with MI reduced consumption during this interval.
We considered whether smoking cessation could be a
manifestation of generalized loss of appetite. However, for
lung cancer there was no difference between current and
former smokers in weight loss before diagnosis (Table 2).
Furthermore, 36.4% of former smokers with lung cancer
gained weight when they quit (Table 3).
Comparison of Former Smokers
The median interval from cessation to diagnosis was
much shorter for lung cancer (2.7 years) than prostate cancer
(24.3 years) or MI (10.0 years). Lifetime tobacco exposure was
much higher for former smokers with lung cancer than the other
groups. The severity of addiction, when smoking the most, was
also much higher among former smokers with lung cancer
(Table 3).
The median difficulty quitting was 3.0 for lung cancer,
1.0 for prostate cancer, and 0.5 for MI. These values must be
interpreted relative to severity of nicotine addiction. For
example, although former smokers with prostate cancer had
little difficulty quitting, they were usually not severely ad-
dicted (median FTND  3.0). For prostate cancer, there was
a significant correlation between difficulty quitting and se-
verity of addiction (R  0.40, p  0.01). In contrast, for lung
cancer and MI, there was no correlation (R  0.13, p  0.36
for lung cancer and R  0.03, p  0.87 for MI).
Smoking cessation rates in the three groups were strat-
ified by severity of nicotine addiction. Among subjects with
moderate to high levels of addiction (FTND 5), the propor-
tion who quit before diagnosis was higher for lung cancer
(45.2%) than for prostate cancer (36.8%) or MI (20%) (p 
0.007).
Among former smokers with lung cancer, 31% reported
quitting with no difficulty (0 on a scale of 0–10), and their
median FTND score was 5. Among former smokers with
prostate cancer, 48% quit with no difficulty, but their median
FTND was only 1. Among former smokers with MI, 50% quit
with no difficulty, and their median FTND was 4. One would
expect that those most severely addicted to nicotine would
have the most difficulty quitting. This was the case for the
former smokers with prostate cancer but not lung cancer or
MI. Even among the subjects with prostate cancer, there were
a number of “outliers” who quit smoking with no difficulty
despite a high-FTND score. One of these patients, who quit
smoking 4.5 years before diagnosis of prostate cancer, with
an FTND score of 8 and difficulty quitting of 0, recently
received a diagnosis of lung cancer, 8.6 years after cessation.
Cotinine Levels
Samples from patients with lung cancer who claimed to
be former smokers were sent for analysis. Cotinine levels
were below limits of quantitation for all but one patient, who
had a cotinine of 58 ng/ml, consistent with his self-reported
status of being on nicotine replacement.
Intervals from Cessation to Diagnosis
The distribution of intervals from cessation to diagnosis
in the three groups is shown in Figure 1. The results are
displayed as intervals from cessation to diagnosis, with the
time of diagnosis set as t  0 and intervals before diagnosis
set as positive. The intervals from cessation to diagnosis were
much shorter for lung cancer than the other two groups.
Furthermore, there was a striking difference in the shape of
the curves for lung cancer compared with the other groups.
We found for prostate cancer and MI that the hazard of
smoking cessation was highest at the longest intervals before
diagnosis. In contrast, for lung cancer, the hazard of smoking
cessation rose at an increasing rate approaching diagnosis
(data not shown).
Symptoms Before Diagnosis
Among all patients with lung cancer, 62% reported symp-
toms before diagnosis. Of the 55 former smokers with lung
cancer, 28 (51%) reported symptoms of their cancer before
diagnosis. Of these 28 patients, only six (11% of all 55 former
smokers) quit smoking after the onset of symptoms. Clinical
records of those patients who quit before diagnosis were re-
viewed and in all cases confirmed their self-report.
In Figure 2, intervals from symptoms to diagnosis were
compared with intervals from cessation to diagnosis for patients
with lung cancer. The intervals from symptoms to diagnosis
were much shorter (median, 2.3 months) than the intervals from
smoking cessation to diagnosis (median, 2.7 years). The six
TABLE 1. Characteristics of Study Patients
Variables
Number (%)
Lung
Cancer
Prostate
Cancer
Myocardial
Infarction
Number 115 (36.5) 101 (32.1) 99 (31.4)
Age at diagnosis
Mean (SD) 63.4 (9.5) 66.7 (8.1) 54.6 (10.3)
Median 62.1 66.8 54.9
Range 38–86 49–83 28–82
Race
White 65 (56.5) 44 (43.6) 59 (59.6)
Black 49 (42.6) 54 (53.5) 35 (35.4)
Hispanic 0 0 5 (5.1)
Other 1 (0.9) 3 (3) 0
Gender
Male 113 (98.2) 101 (100) 97 (98)
Female 2 (1.7) N/A 2 (2)
Stage
I 19 (16.5) 2 (2) N/A
II 9 (7.8) 80 (79.2)
III 39 (33.9) 9 (8.9)
IV 48 (41.7) 10 (9.9)
Smoking status
Never 0 21 (20.8) 15 (15.2)
Current 60 (52.2) 32 (31.7)a 58 (58.6)
Former 55 (47.8) 48 (47.5)a 26 (26.3)
a Five subjects, all with prostate cancer were categorized as ever smokers based on
daily pipe smoking (one former smoker) or cigar smoking (one current and three former
smokers).
N/A, not applicable.
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patients with lung cancer who had symptoms at the time of
smoking cessation are highlighted.
Comparison with KRCC Patients
To determine whether our results in a group of veterans
with lung cancer can be generalized to the civilian lung cancer
population, we reexamined the data from our study done at the
KRCC. Of the 178 patients included in that study, only four
were never smokers, and 103 were former smokers at diagnosis.
Because all former smokers with lung cancer in the VA study
were men, we compared the distribution of intervals from
cessation to diagnosis for all male subjects in the KRCC (n 
67) and VA studies (n  53, excluding two subjects who had
quit 52 and 49 years before diagnosis). There was no significant
difference between the two groups (Figure 3).
Comparison of SCLC with NSCLC
The VA study included 21 patients with SCLC, and
only eight of these were former smokers. These numbers
were too small for robust comparisons of intervals from
TABLE 2. Comparison of Current vs. Former Smokers
Variables
Number (%)
Lung Cancer Prostate Cancer Myocardial Infarction
Current
(n  60)
Former
(n  55) pa
Current
(n  32)
Former
(n  48) pa
Current
(n  58)
Former
(n  26) pa
Age at diagnosis
Mean 59.7 67.5 0.0001 61.1 69.0 0.0001 52.7 56.6 NS
Median 57.8 68.0 0.0001 61.6 69.0 0.0001 54.3 57.2 NS
Stage N/A N/A
I 8 (13.3) 11 (20.0) NS 2 (6.3) 0 NS
II 4 (6.7) 5 (9.1) 23 (71.9) 38 (79.2)
III 26 (43.3) 13 (23.6) 5 (15.6) 3 (6.3)
IV 22 (36.7) 26 (47.3) 2 (6.3) 7 (14.6)
Histology N/A N/A N/A N/A
Small cell 13 (21.7) 8 (14.6) NS
Adeno 14 (23.3) 19 (34.6)
Squamous 10 (16.7) 13 (23.6)
Large cell 2 (3.3) 0
Other 21 (35.0) 15 (27.3)
Lifetime tobacco exposure
Years smoked
Mean 43.8 43.9 NS 44.1 27.1 0.001 38.2 25.9 0.001
Median 42.8 44.0 44.4 30.2 41.3 27.8
Maximum cigarettes/d
Mean 37.2 32.6 NS 31.7 19.4 0.001 34.7 32.0 NS
Median 40.0 30.0 30.0 15.0 30.0 25.0
Years 1 pack per day
Mean 33.2 30.1 NS 28.5 8.3 0.001 26.5 13.4 0.002
Median 37.0 30.0 35.0 0 30.0 7.5
Severity of addiction
FTND
Mean 6.6 5.9 NS 6.2 3.4 0.0001 6.2 4.4 0.003
Median 7.0 7.0 NS 7.0 3.0 0.0002 6.5 4.0 0.01
Reduction in smoking
Cut down 50% or more 19/50 (38.0%) N/A N/A 5/29 (17.2%) N/A N/A 2/50 (4.0%) N/A p  0.0001
(comparison
between
three
groups)
No. of quit attempts
Mean 9.1 4.2 0.05 5.7 4.9 NS 4.6 3.1 NS
Median 3.0 3.0 NS 3.0 2.0 NS 3.0 2.0 NS
Weight loss in year before
diagnosis
20/59 (33.9%) 15/55 (27.3%) NS 7/32 (21.9%) 4/48 (8.3%) NS 3/58 (5.2%) 0/26 (0%) NS
a Chi-square test for categorical variables, and Kruskal-Wallis test for continuous variables.
N/A, not applicable; NS, not significant; FTND, Fagerström Test for Nicotine Dependence.
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cessation to diagnosis between the two major histologic types
of lung cancer, SCLC and NSCLC. Therefore, we combined
the VA and male KRCC data sets (55 SCLC and 67 NSCLC).
The median interval from cessation to diagnosis was much
shorter for SCLC (6 months) than for NSCLC (3.5 years).
When subjects who had quit smoking more than 5 years
before diagnosis were excluded, the difference in distribution
of intervals from cessation to diagnosis for SCLC compared
with NSCLC was significant (p  0.005 by log rank).
DISCUSSION
This study confirms our clinical observation that pa-
tients with lung cancer frequently stop smoking before diag-
nosis, usually before clinical symptoms, and often with very
little effort. All patients with lung cancer in this study had
smoked in their lives, and 48% of them had stopped before
diagnosis. Only 11% of these were symptomatic when they
quit. These results challenge the belief that patients with lung
cancer usually stop smoking because of disease symptoms.
For prostate cancer and MI, former smokers had
smoked less heavily and were less severely addicted than
continuing smokers, as expected. In contrast, for lung cancer,
there was no difference between current and former smokers
in lifetime tobacco exposure or severity of addiction when
smoking most heavily. Despite this, 31% of them quit with no
difficulty. Even among continuing smokers with lung cancer,
38% had reduced their tobacco use by 50% in the year
before diagnosis, suggesting a spontaneous decrease in their
TABLE 3. Comparison of Former Smokers
Variables
Lung
Cancer
(n  55)
Prostate
Cancer
(n  48)
Myocardial
Infarction
(n  26) pa
Interval from cessation to diagnosis (yr)
Mean 7.6 23.4 12.7 0.0001
Median 2.7 24.3 10.0 0.0001
Lifetime tobacco exposure
Years smoked
Mean 43.9 27.1 25.9 0.0001
Median 44.0 30.2 27.8 0.0001
Maximum cigarettes/d
Mean 32.6 19.4 32.0 0.002
Median 30.0 15.0 25.0 0.0002
Years 1 pack per day
Mean 30.1 8.3 13.4 0.0001
Median 30 0 7.5 0.0001
Severity of addiction
FTND
Mean 5.9 3.4 4.4 0.0002
Median 7.0 3.0 4.0 0.0005
Quitting information
Difficulty quitting (out of 10)
Mean 3.4 2.2 2.1 NS
Median 3.0 1.0 0.5 NS
Number of quit attempts in past n  54 n  40 n  26
Mean 4.2 4.9 3.1 NS
Median 3.0 2.0 2.0 NS
Proportion of subjects with
FTND 5 who stopped smoking
(denominator includes current
and former smokers)
38/84 (45.2%) 14/38 (36.8%) 12/60 (20%) 0.007
Quit with no difficulty (0/10) 17/55 (31%) 20/42 (48%) 13/26 (50%) NS
Median FTND of those who quit with
no difficulty
5 1 4 NS
Severity of withdrawal symptoms
(out of 10)
No withdrawal symptoms (0/10) 20/51 (39%) 20/40 (50%) 13/26 (50%)
Mean 2.8 1.9 2.4 NS
Median 2.0 0.5 0.5 NS
Weight gain at cessation 20/55 (36.4%) 20/42 (47.6%) 19/26 (73.1%)
a Chi-square test for categorical variables, and Kruskal-Wallis test for continuous variables.
NS, not significant; FTND, Fagerström Test for Nicotine Dependence.
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desire for nicotine. For patients with lung cancer, we did not
find any correlation between smoking cessation and weight
loss, indicating that smoking cessation is not usually a man-
ifestation of anorexia associated with cancer.
A causal relationship between lung cancer diagnosis
and prior symptoms is generally accepted. We suggest that
there may also be a causal relationship between the presence
of lung cancer and smoking cessation and that smoking
cessation may itself be a symptom in some lung cancer cases.
Two groups have argued that lung cancers may be triggered
by smoking cessation.15,16 However, initiation and promotion
of lung cancer is a process that develops over many years.
With a median interval from cessation to diagnosis of 2.7
years, the majority of former smokers with lung cancer in this
study likely harbored their cancer at the time of cessation.
Furthermore, the uncharacteristic ease of quitting in some of
the lung cancer cases suggests that another process is in-
volved. Thus, the notion that ongoing smoking protects from
lung cancer is untenable.
A more plausible explanation is that some lung cancers
may somehow lead to smoking cessation. The most widely
held belief is that smokers quit because of cancer symp-
toms.4,5 However, we have shown that most patients with
lung cancer do not quit for this reason. We speculate that
some lung cancers may produce a factor that blocks or
emulates the effects of nicotine. For example, there are a
variety of noncompetitive endogenous modulators of nico-
tinic responses, including histamine, neurokinins, and other
tachykinins,17–19 which are produced by some lung can-
cers.20,21 Alternatively, substances that modulate dopamine re-
lease within the mesolimbic system could be antiaddictive.
Certain endogenous opioids (e.g., dynorphins), which are known
to be produced by some lung cancers,22,23 could possibly play
such a role. A recent study showed that neurologic damage
involving the insula, a region of the brain implicated in regula-
tion of conscious cravings, can result in “disruption of smoking
addiction.”24 This effect may be mediated through insular hypo-
cretin transmission.25 Whether spontaneous smoking cessation
in patients with lung cancer could be caused by such a factor is
another intriguing possibility.
The marked difference in age between current and
former smokers was unexpected, although it has been previ-
ously reported.26,27 In all three diagnostic groups, the median
age of current smokers was much less than that of former
smokers. The difference was most striking for lung cancer
(10.2 years) and prostate cancer (7.4 years) but less marked
for MI (2.8 years). One possible explanation for this differ-
ence is that current smokers may have higher rates of com-
peting causes of mortality than former smokers. Although the
risk of lung cancer goes up for a number of years after
smoking cessation, as outlined earlier, the risk of other
illnesses, in particular cardiovascular diseases, goes down
rapidly.28,29
Excess competing mortality among continuing smokers
is unlikely to be the only explanation for the large age
difference between current and former smokers with lung
cancer and prostate cancer. With a median interval of 2.7
years from cessation to diagnosis, it is likely that the majority
of former smokers with lung cancer harbored their cancer at
the time of quitting. The sudden removal of the growth-
promoting effects of nicotine and other components of to-
bacco smoke,22,30–33 as well as angiogenic effects of nico-
tine,34,35 may have delayed the presentation of cancer among
the former smokers. Nevertheless, it is difficult to explain the
fact that the age difference between current and former
FIGURE 1. Kaplan-Meier distribution of intervals from ces-
sation to diagnosis for lung cancer, myocardial infarction
(MI), and prostate cancer. The difference between the
groups was highly significant (p  0.0001).
FIGURE 2. Comparison of intervals from symptoms to di-
agnosis and from cessation to diagnosis for patients with
lung cancer. Survival curves were generated using the
Kaplan-Meier method. The probability of having stopped
smoking is shown on the left y axis and the probability of
having symptoms is shown on the right y axis. Those pa-
tients who were symptomatic at quitting are identified with
arrows.
FIGURE 3. Kaplan-Meier distribution of intervals from ces-
sation to diagnosis for patients with lung cancer from the
Veterans Affairs (VA) and the Kingston Regional Cancer Cen-
tre (KRCC). There was no significant difference between the
two groups (p  0.64).
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smokers with lung cancer far exceeds the median interval
from cessation to diagnosis in this group of patients.
With a median interval of 24.3 years from cessation to
diagnosis, the majority of former smokers with prostate
cancer likely developed their cancer after they stopped smok-
ing. Although smoking is not considered a cause of prostate
cancer, it is possible that continued smoking could promote
the growth of established tumors, leading to earlier presen-
tation in current compared with former smokers.
Our study has a number of limitations. Because it is a
preliminary report, the number of patients in each group is
small. The three groups were not matched for age, sex, or
demographic factors, thereby limiting comparisons between
groups. Furthermore, because the subjects underwent a single
interview, we have no information on their smoking status
after diagnosis.
Although we noted whether the subjects had symptoms
of their disease when they quit, we did not record the date of
first radiologic abnormality or suspicion of lung cancer. Thus,
some patients may have quit because they suspected they
had lung cancer, even in the absence of symptoms. Fur-
thermore, because subjects were identified at the time of
diagnosis and then asked to recall their past smoking
habits, our results may be biased from retrospective recall.
Although the reliability of retrospective assessment of
nicotine dependence is good,36 a prospective study will be
required to eliminate this potential bias.
It may be difficult for patients with lung cancer and
their physicians to ascertain the exact time of onset of
symptoms. These patients often have longstanding pulmo-
nary symptoms due to many years of smoking. We believe
that patients with lung cancer themselves are in the best
position to judge when a new symptom or a change in a
chronic symptom could be identified as the initial symptom of
their cancer. Thus, we have relied on the subject’s self-report
of whether and when they had symptoms of their disease.
Our study also has a number of strengths. Our
hypothesis is novel and has many clinical and biological
implications. Our reanalysis of the KRCC dataset confirms
that our results are applicable to the general population of
patients with lung cancer. The fact that in all former
smokers with lung cancer, the cotinine levels confirmed
self-reported smoking status indicates that the smoking
histories are reliable.
Further investigation will include a prospective cohort
study to determine the outcome of subjects in the general
population who have quit smoking, especially without diffi-
culty. To determine the true risk of lung cancer after smoking
cessation, smoking status must be determined relative to time
of diagnosis.
We believe that long-term heavy smokers who quit,
especially without difficulty, are at risk for having or devel-
oping lung cancer. Our study could be dangerously misinter-
preted to suggest that those who have smoked heavily for
most of their lives might be better off to continue smoking.
This is clearly not the case. All smokers, especially heavy
smokers, must be strongly encouraged to stop.
The simple observation that many patients with lung
cancer quit smoking without difficulty before diagnosis has
many implications. Recognition of this phenomenon as a
presenting symptom of lung cancer could result in earlier
diagnosis of this common, highly lethal cancer, which is
curable only when diagnosed at an early stage. An under-
standing of the biological basis of this phenomenon could
lead to new strategies for smoking cessation.
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